HR | 95 % CI | p-values | |
---|---|---|---|
Age | 0.99 | 0.96–1.02 | 0.612 |
MPO + IL17- | 0.64 | 0.17–2.48 | 0.518 |
MPO-IL17+ | 0.26 | 0.10–0.69 | 0.006 |
MPO + IL17+ | 0.23 | 0.07–0.73 | 0.013 |
Residual disease <2 cm | 1.03 | 0.48–2.20 | 0.949 |
Residual disease >2 cm | 3.93 | 1.47–10.52 | 0.007 |
N of chemotherapy cycles | 1.16 | 0.89–1.52 | 0.276 |
FIGO IIIA | 0.08 | 0.00–1.88 | 0.115 |
FIGO IIIB | 0.58 | 0.05–6.48 | 0.661 |
FIGO IIIC | 0.40 | 0.04–3.61 | 0.413 |
FIGO IV | 0.59 | 0.06–6.00 | 0.652 |